Age-dependent Immune Response to the Biontech/Pfiz Vaccination

Clinical Infectious Diseases

73, 2065-2072

DOI: 10.1093/cid/ciab381

Citation Report

#	Article	IF	Citations
1	Comparison of Antibody and T Cell Responses Induced by Single Doses of ChAdOx1 nCoV-19 and BNT162b2 Vaccines. Immune Network, 2021, 21, e29.	1.6	14
2	Declined Antibody Responses to COVID-19 mRNA Vaccine within First Three Months. SSRN Electronic Journal, 0, , .	0.4	2
3	The future of SARSâ€CoVâ€2 vaccines in transplant recipients: To be determined. American Journal of Transplantation, 2021, 21, 2629-2630.	2.6	6
4	Anti-SARS-CoV-2 Antibodies Testing in Recipients of COVID-19 Vaccination: Why, When, and How?. Diagnostics, 2021, 11, 941.	1.3	45
6	Utility of Different Surrogate Enzyme-Linked Immunosorbent Assays (sELISAs) for Detection of SARS-CoV-2 Neutralizing Antibodies. Journal of Clinical Medicine, 2021, 10, 2128.	1.0	51
7	Flavonoids are promising safe therapy against COVID-19. Phytochemistry Reviews, 2022, 21, 291-312.	3.1	87
8	Is a single COVID-19 vaccine dose enough in convalescents ?. Human Vaccines and Immunotherapeutics, 2021, 17, 2959-2961.	1.4	10
9	Can integrated post-exposure vaccination against SARS-COV2 mitigate severe disease?. Lancet Regional Health - Europe, The, 2021, 5, 100118.	3.0	2
11	Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly. Rheumatology International, 2021, 41, 1429-1440.	1.5	71
12	Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine. Diagnostics, 2021, 11, 1135.	1.3	70
13	Impact of Prior Influenza and Pneumoccocal Vaccines on Humoral and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination. Vaccines, 2021, 9, 615.	2.1	15
14	BNT162b2 mRNA SARS-CoV-2 Vaccine Elicits High Avidity and Neutralizing Antibodies in Healthcare Workers. Vaccines, 2021, 9, 672.	2.1	32
15	Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study. Lancet Infectious Diseases, The, 2021, 21, 1529-1538.	4.6	146
16	Antibody response after one and two jabs of the BNT162b2 vaccine in nursing home residents: The CONsortâ€19 study. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 271-281.	2.7	30
17	Age and Gender Disparities in Adverse Events Following COVID-19 Vaccination: Real-World Evidence Based on Big Data for Risk Management. Frontiers in Medicine, 2021, 8, 700014.	1.2	41
18	Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine. Vaccines, 2021, 9, 781.	2.1	28
20	Impaired Immune Response to SARS-CoV-2 Vaccination in Dialysis Patients and in Kidney Transplant Recipients. Kidney360, 2021, 2, 1491-1498.	0.9	37
22	Characterization of the Diagnostic Performance of a Novel COVID-19 PETIA in Comparison to Four Routine N-, S- and RBD-Antigen Based Immunoassays. Diagnostics, 2021, 11, 1332.	1.3	4

#	Article	IF	Citations
23	Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine. Lancet Regional Health - Europe, The, 2021, 9, 100178.	3.0	231
24	Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous dual vaccination in older people. Immunity and Ageing, 2021, 18, 34.	1.8	60
26	Factors Affecting the Antibody Immunogenicity of Vaccines against SARS-CoV-2: A Focused Review. Vaccines, 2021, 9, 869.	2.1	17
27	Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers. Vaccines, 2021, 9, 857.	2.1	49
28	Outbreak of SARS-CoV-2 B.1.1.7 Lineage after Vaccination in Long-Term Care Facility, Germany, Februaryâ€“March 2021. Emerging Infectious Diseases, 2021, 27, 2169-2173.	2.0	17
29	Serological Response to the BNT162b2 COVID-19 mRNA Vaccine in Adolescent and Young Adult Kidney Transplant Recipients. Transplantation, 2021, 105, e226-e233.	0.5	46
30	The dynamics of quantitative SARSâ€CoVâ€2 antispike IgG response to BNT162b2 vaccination. Journal of Medical Virology, 2021, 93, 6813-6817.	2.5	8
31	COVID-19 Pneumonia in Vaccinated Population: A Six Clinical and Radiological Case Series. Medicina (Lithuania), 2021, 57, 891.	0.8	12
32	Robust Antibody Responses to the BNT162b2 mRNA Vaccine Occur Within a Week After the First Dose in Previously Infected Individuals and After the Second Dose in Uninfected Individuals. Frontiers in Immunology, 2021, 12, 722766.	2.2	20
33	Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany. Emerging Infectious Diseases, 2021, 27, 2174-2178.	2.0	67
34	Evaluation of Antibody Responses to COVID-19 Vaccines among Solid Tumor and Hematologic Patients. Cancers, 2021, 13, 4312.	1.7	11
35	Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients. Journal of Hepatology, 2021, 75, 435-438.	1.8	288
36	Initial SARS-CoV-2 vaccination response can predict booster response for BNT162b2 but not for AZD1222. International Journal of Infectious Diseases, 2021, 110, 309-313.	1.5	13
38	Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5â€“6 weeks post vaccine in participants aged 80 years or older: an exploratory analysis. The Lancet Healthy Longevity, 2021, 2, e554-e560.	2.0	34
39	The temporal course of T- and B-cell-responses to vaccination with BNT162b2 and mRNA-1273. Clinical Microbiology and Infection, 2021, , .	2.8	22
40	Antibodies against SARS-CoV-2 Time Course in Patients and Vaccinated Subjects: An Evaluation of the Harmonization of Two Different Methods. Diagnostics, 2021, 11, 1709.	1.3	8
41	Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Regional Health - Europe, The, 2021, 10, 100208.	3.0	446
42	COVID-19 Vaccinations: A Comprehensive Review of Their Safety and Efficacy in Special Populations. Vaccines, 2021, 9, 1097.	2.1	27

#	Article	IF	Citations
43	Does reactogenicity after a second injection of the BNT162b2 vaccine predict spike IgG antibody levels in healthy Japanese subjects?. PLoS ONE, 2021, 16, e0257668.	1.1	33
44	Comparison of SARS-CoV-2 Antibody Response by Age Among Recipients of the BNT162b2 vs the mRNA-1273 Vaccine. JAMA Network Open, 2021, 4, e2124331.	2.8	85
45	Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination. Vaccine, 2021, 39, 5337-5340.	1.7	31
46	Evaluation of Three Anti-SARS-CoV-2 Serologic Immunoassays for Post-Vaccine Response. journal of applied laboratory medicine, The, 2022, 7, 57-65.	0.6	18
47	A single dose of the Biontech/Pfizer BNT162b2 vaccine protected elderly residents from severe COVIDâ€19 during a SARSâ€coronavirusâ€2 outbreak in a senior citizen home in Germany. Immunity, Inflammation and Disease, 2021, 9, 1809-1814.	1.3	4
48	Discovery of potential SARS-CoV 3CL protease inhibitors from approved antiviral drugs using: virtual screening, molecular docking, pharmacophore mapping evaluation and dynamics simulation. Journal of Biomolecular Structure and Dynamics, 2021, , 1-18.	2.0	6
49	Population science with individual-level data make for better policies. Lancet Respiratory Medicine,the, 2021, 9, 942-943.	5.2	1
51	Intensity of mycophenolate mofetil treatment is associated with an impaired immune response to SARS-CoV-2 vaccination in kidney transplant recipients. American Journal of Transplantation, 2022, 22, 634-639.	2.6	97
52	BNT162b2 Vaccination Elicits Strong Serological Immune Responses Against SARS-CoV-2 Including Variants of Concern in Elderly Convalescents. Frontiers in Immunology, 2021, 12, 743422.	2.2	10
53	SARS-CoV-2, COVID-19 and the aging immune system. Nature Aging, 2021, 1, 769-782.	5.3	208
54	Reactogenicity Correlates Only Weakly with Humoral Immunogenicity after COVID-19 Vaccination with BNT162b2 mRNA (ComirnatyÂ®). Vaccines, 2021, 9, 1063.	2.1	27
55	Age and Smoking Predict Antibody Titres at 3 Months after the Second Dose of the BNT162b2 COVID-19 Vaccine. Vaccines, 2021, 9, 1042.	2.1	64
57	Beta SARS-CoV-2 variant and BNT162b2 vaccine effectiveness in long-term care facilities in France. The Lancet Healthy Longevity, 2021, 2, e685-e687.	2.0	27
58	Direct and Indirect Effectiveness of mRNA Vaccination against Severe Acute Respiratory Syndrome Coronavirus 2 in Long-Term Care Facilities, Spain. Emerging Infectious Diseases, 2021, 27, 2595-2603.	2.0	39
59	Overview of approved and upcoming vaccines for SARS-CoV-2: a living review. Oxford Open Immunology, 2021, 2, iqab010.	1.2	18
60	Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies. Frontiers in Immunology, 2021, 12, 727850.	2.2	69
61	SARS-CoV-2 Infection in Fully Vaccinated Individuals of Old Age Strongly Boosts the Humoral Immune Response. Frontiers in Medicine, 2021, 8, 746644.	1.2	8
62	Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers. Vaccines, 2021, 9, 1223.	2.1	48

#	Article	IF	Citations
63	Use of Quantitative Dried Blood Spots to Evaluate the Post-Vaccination Level of Neutralizing Antibodies against SARS-CoV-2. Life, 2021, 11, 1125.	1.1	6
64	Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals. Life, 2021, 11, 1077.	1.1	25
66	Immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in elderly people over 85Âyears of age in Greece: the GREVAXIMO study. Aging Clinical and Experimental Research, 2021, 33, 3385.	1.4	3
68	Active Surveillance of Adverse Events in Healthcare Workers Recipients After Vaccination with COVID-19 BNT162b2 Vaccine (Pfizer-BioNTech, Comirnaty): A Cross-Sectional Study. Journal of Community Health, 2022, 47, 211-225.	1.9	30
69	Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents?. Aging Clinical and Experimental Research, 2021, 33, 3151-3160.	1.4	16
70	The COVID-19 mRNA BNT163b2 Vaccine Was Well Tolerated and Highly Immunogenic in Young Adults in Long Follow-Up after Haematopoietic Stem Cell Transplantation. Vaccines, 2021, 9, 1209.	2.1	16
72	Robust SARS-CoV-2 Antibody Responses in Asian COVID-NaÃ¯ve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine. Vaccines, 2021, 9, 1241.	2.1	12
73	A practical approach to SARS-CoV-2 testing in a pre and post-vaccination era. Journal of Clinical Virology Plus, 2021, 1, 100044.	0.4	2
74	SARS-CoV-2 mRNA Vaccines in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Immunogenicity and Reactogenicity. Clinical Infectious Diseases, 2021, , .	2.9	18
75	COVID-19 Breakthrough Infections and Transmission Risk: Real-World Data Analyses from Germanyâ€™s Largest Public Health Department (Cologne). Vaccines, 2021, 9, 1267.	2.1	24
77	Willingness to Receive the Booster COVID-19 Vaccine Dose in Poland. Vaccines, 2021, 9, 1286.	2.1	117
78	Human IgM and IgG Responses to an Inactivated SARS-CoV-2 Vaccine. Current Medical Science, 2021, 41, 1081-1086.	0.7	11
79	Poor Antibody Response to BioNTech/Pfizer Coronavirus Disease 2019 Vaccination in Severe Acute Respiratory Syndrome Coronavirus 2â€“Naive Residents of Nursing Homes. Clinical Infectious Diseases, 2022, 75, e695-e704.	2.9	23
80	Mechanisms underpinning poor antibody responses to vaccines in ageing. Immunology Letters, 2022, 241, 1-14.	1.1	28
81	Anti-Spike SARS-CoV-2 IgG Assessment with a Commercial Assay during a 4-Month Course after COVID-19 Vaccination. Vaccines, 2021, 9, 1367.	2.1	11
82	Are COVID-19 Vaccine Boosters Needed? The Science behind Boosters. Journal of Virology, 2022, 96, JVI0197321.	1.5	35
83	Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People. Frontiers in Immunology, 2021, 12, 778679.	2.2	54
84	Anti-SARS-CoV-2 Spike Protein RBD Antibody Levels After Receiving a Second Dose of ChAdOx1 nCov-19 (AZD1222) Vaccine in Healthcare Workers: Lack of Association With Age, Sex, Obesity, and Adverse Reactions. Frontiers in Immunology, 2021, 12, 779212.	2.2	35

#	Article	IF	Citations
85	Effect of BCG Revaccination on Occupationally Exposed Medical Personnel Vaccinated against SARS-CoV-2. Cells, 2021, 10, 3179.	1.8	20
87	Antibody Response 3 Months after 2 Doses of BNT162b2 mRNA COVID-19 Vaccine in Residents of Long-Term Care Facilities. Gerontology, 2021, , 1-7.	1.4	7
88	High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients. Microbiology Spectrum, 2021, 9, e0096521.	1.2	17
89	Reactogenicity and Immunogenicity of the Pfizer and AstraZeneca COVID-19 Vaccines. Frontiers in Immunology, 2021, 12, 794642.	2.2	26
90	Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?. Human Vaccines and Immunotherapeutics, 2024, 17, 4714-4740.	1.4	16
91	Age-Dependent Reduction in Neutralization against Alpha and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced Immunity. Microbiology Spectrum, 2021, 9, e0056121.	1.2	15
92	The intestinal microbiota and improving the efficacy of COVID-19 vaccinations. Journal of Functional Foods, 2021, 87, 104850.	1.6	23
93	Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older. Journal of Korean Medical Science, 2021, 36, e318.	1.1	12
94	Correlation between Reactogenicity and Immunogenicity after the ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccination. Immune Network, 2021, 21, e41.	1.6	8
95	Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine. Journal of Korean Medical Science, 2021, 36, e311.	1.1	33
96	Significant Reduction in Vaccine-Induced Antibody Levels and Neutralization Activity Among Healthcare Workers and Nursing Home Residents 6 Months Following Coronavirus Disease 2019 BNT162b2 mRNA Vaccination. Clinical Infectious Diseases, 2022, 75, e884-e887.	2.9	31
98	COVID-19 outbreak in a long-term care facility in Kelowna, British Columbia after rollout of COVID-19 vaccine in March 2021. Canada Communicable Disease Report, 2021, 47, 543-552.	0.6	2
99	COVID-19 cluster in vaccinated healthcare workers in Mayotte. Infectious Diseases Now, 2022, , .	0.7	0
100	A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern. Cell Reports Medicine, 2022, 3, 100486.	3.3	16
101	Naturally occurring anthraquinones as potential inhibitors of SARS-CoV-2 main protease: an integrated computational study. Biologia (Poland), 2022, 77, 1121-1134.	0.8	5
102	Analysis of Neutralization Titers against SARS-CoV-2 in Health-Care Workers Vaccinated with Prime-Boost mRNAâ€“mRNA or Vectorâ€“mRNA COVID-19 Vaccines. Vaccines, 2022, 10, 75.	2.1	8
103	Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2. Microbiology Spectrum, 2022, 10, e0118121.	1.2	15
105	Predictive Factors for Neutralizing Antibody Levels Nine Months after Full Vaccination with BNT162b2: Results of a Machine Learning Analysis. Biomedicines, 2022, 10, 204.	1.4	7

#	Article	IF	Citations
106	Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases. Viruses, 2022, 14, 207.	1.5	27
107	Hypertension Is Associated With Antibody Response and Breakthrough Infection in Health Care Workers Following Vaccination With Inactivated SARS-CoV-2. SSRN Electronic Journal, 0, , .	0.4	2
108	Are convalescent plasma stocks collected during former COVIDâ€19 waves still effective against current <scp>SARSâ€CoV</scp>â€2 variants?. Vox Sanguinis, 2022, 117, 641-646.	0.7	8
109	Humoral response to the SARS-CoV-2 BNT162b2 mRNA vaccine: Real-world data from a large cohort of healthcare workers. Vaccine, 2022, 40, 650-655.	1.7	17
110	Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals. Med, 2022, 3, 137-153.e3.	2.2	19
111	Loss of humoral response 3 months after SARS-CoV-2 vaccination in the CKD spectrum: the multicentric SENCOVAC study. Nephrology Dialysis Transplantation, 2022, 37, 994-999.	0.4	14
112	SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study. Vaccine, 2022, 40, 206-212.	1.7	20
113	Effects of Loigolactobacillus coryniformis K8 CECT 5711 on the Immune Response of Elderly Subjects to COVID-19 Vaccination: A Randomized Controlled Trial. Nutrients, 2022, 14, 228.	1.7	18
114	Two Doses of BNT162b2 mRNA Vaccine in Patients after Hematopoietic Stem Cell Transplantation: Humoral Response and Serological Conversion Predictors. Cancers, 2022, 14, 325.	1.7	16
115	Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in NaÃ¯ve and Previously Infected Individuals: A Comparative Study. Vaccines, 2022, 10, 191.	2.1	2
116	COVID-19 Vaccination for Frail Older Adults in Singapore - Rapid Evidence Summary and Delphi Consensus Statements. Journal of Frailty & Aging,the, 2022, 11, 236-241.	0.8	3
117	Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study. Lancet Microbe, The, 2022, 3, e274-e283.	3.4	51
118	Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines. Canadian Journal of Infectious Diseases and Medical Microbiology, 2022, 2022, 1-16.	0.7	2
119	Humoral and Cellular Responses to COVID-19 Vaccination Indicate the Need for Post-Vaccination Testing in Frail Population. Vaccines, 2022, 10, 260.	2.1	14
120	COVIDâ€19Â vaccination in patients receiving allergen immunotherapy (AIT) or biologicalsâ€”EAACI recommendations. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2313-2336.	2.7	12
122	Vaccination and COVID-19 Dynamics in Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 395-402.	2.2	33
123	Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older Adults. Journal of Infectious Diseases, 2022, 225, 1129-1140.	1.9	65
124	Sustained but Declining Humoral Immunity Against SARS-CoV-2 at 9 Months Postvaccination With BNT162b2: A Prospective Evaluation in 309 Healthy Individuals. HemaSphere, 2022, 6, e677.	1.2	17

#	Article	IF	Citations
125	Attenuation of Antibody Titers from 3 to 6 Months after the Second Dose of the BNT162b2 Vaccine Depends on Sex, with Age and Smoking Risk Factors for Lower Antibody Titers at 6 Months. Vaccines, 2021, 9, 1500.	2.1	22
126	Antibody response of smokers to the COVID-19 vaccination: Evaluation based on cigarette dependence. Drug Discoveries and Therapeutics, 2022, 16, 78-84.	0.6	5
127	Booster BNT162b2 COVID-19 Vaccination Increases Neutralizing Antibody Titers Against the SARS-CoV-2 Omicron Variant in Both Young and Elderly Adults. Journal of Korean Medical Science, 2022, 37, e70.	1.1	10
128	Anti-SARS-CoV-2 Neutralizing Antibody Responses after Two Doses of ChAdOx1 nCoV-19 vaccine (AZD1222) in Healthcare Workers. Infection and Chemotherapy, 2022, 54, 140.	1.0	4
129	Population antibody responses following COVID-19 vaccination in 212,102 individuals. Nature Communications, 2022, 13, 907.	5.8	94
130	COVID-19: Comparison of immunogenicity response between natural and post-vaccination infections. F1000Research, 0, 11, 212.	0.8	0
131	Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy. Npj Vaccines, 2022, 7, 28.	2.9	64
133	Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 Pfizer-BioNTech mRNA vaccination: a systematic review. Critical Reviews in Clinical Laboratory Sciences, 2022, 59, 373-390.	2.7	64
134	Humoral and Cellular Immune Responses of Solid Organ Transplant Patients on Belatacept to Three Doses of mRNA-Based Anti-SARS-CoV-2 Vaccine. Vaccines, 2022, 10, 354.	2.1	8
135	Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination. Vaccines, 2022, 10, 285.	2.1	13
137	A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant. Vaccines, 2022, 10, 508.	2.1	5
139	Waning effectiveness of SARS-CoV-2 mRNA vaccines in older adults: a rapid review. Human Vaccines and Immunotherapeutics, 2022, 18, 1-6.	1.4	20
140	Immunological features that associate with the strength of antibody responses to BNT162b2 mRNA vaccine against SARS-CoV-2. Vaccine, 2022, 40, 2129-2133.	1.7	2
141	Decline of Humoral and Cellular Immune Responses Against SARS-CoV-2 6 Months After Full BNT162b2 Vaccination in Hospital Healthcare Workers. Frontiers in Immunology, 2022, 13, 842912.	2.2	31
142	COVID-19 Antibodies in Vaccinated Healthcare Workers: The Security Currency. Cureus, 2022, 14, e23383.	0.2	2
143	Assessment of antibody titer after third doses of COVID-19 mRNA vaccination in healthy volunteers. Laboratoriums Medizin, 2022, 46, 151-153.	0.1	3
144	Sero-survey on long-term care facility residents reveals increased risk of sub-optimal antibody response to BNT162b2: implications for breakthrough prevention. BMC Geriatrics, 2022, 22, 191.	1.1	7
145	Persistence of Immune Response in Health Care Workers After Two Doses BNT162b2 in a Longitudinal Observational Study. Frontiers in Immunology, 2022, 13, 839922.	2.2	26

#	Article	IF	Citations
146	Fever after Vaccination against SARS-CoV-2 with mRNA-Based Vaccine Associated with Higher Antibody Levels during 6 Months Follow-Up. Vaccines, 2022, 10, 447.	2.1	12
147	Medium-to-Long-Term Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine: A Retrospective Cohort Study. Vaccines, 2022, 10, 417.	2.1	4
148	Sex, Age, and Ethnic Background Shape Adaptive Immune Responses Induced by the SARS-CoV-2 mRNA Vaccine. Frontiers in Immunology, 2022, 13, 786586.	2.2	13
149	Current Developments and Challenges of mRNA Vaccines. Annual Review of Biomedical Engineering, 2022, 24, 85-109.	5.7	39
150	Population differences in antibody response to SARSâ€CoVâ€2 infection and BNT162b2 vaccination. FASEB Journal, 2022, 36, e22223.	0.2	7
151	Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study. The Lancet Healthy Longevity, 2022, 3, e166-e175.	2.0	9
152	Trajectory of IgG to SARS-CoV-2 After Vaccination With BNT162b2 or mRNA-1273 in an Employee Cohort and Comparison With Natural Infection. Frontiers in Immunology, 2022, 13, 850987.	2.2	35
153	Relation of fever intensity and antipyretic use with specific antibody response after two doses of the BNT162b2 mRNA vaccine. Vaccine, 2022, 40, 2062-2067.	1.7	26
154	Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination. Vaccines, 2022, 10, 491.	2.1	4
155	Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study. Vaccines, 2022, 10, 382.	2.1	19
156	The DiaCoVAb Study in South Italy: Immune Response to SARS-CoV-2 Vaccination in Dialysis Patients. Kidney and Blood Pressure Research, 2022, 47, 467-474.	0.9	9
157	Timely Monitoring COVID-19 Vaccine Protection, Berlin, Germany, April 15th to December 15th, 2021. International Journal of Public Health, 2022, 67, 1604633.	1.0	0
158	Severe Breakthrough COVID-19 Cases during Six Months of Delta Variant (B.1.617.2) Domination in Poland. Vaccines, 2022, 10, 557.	2.1	15
159	Micronutrients to Support Vaccine Immunogenicity and Efficacy. Vaccines, 2022, 10, 568.	2.1	10
160	SARS-CoV-2 Spike S1-specific IgG kinetic profiles following mRNA or vector-based vaccination in the general Dutch population show distinct kinetics. Scientific Reports, 2022, 12, 5935.	1.6	17
161	An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine. Vaccines, 2022, 10, 563.	2.1	3
162	The Fluctuation Trend of Serum Anti-SARS-CoV-2 IgM/IgG Antibodies Seroprevalence in the Non-COVID-19 Infected Population and Correlation with Peripheral Blood Leukocyte Parameters in Beijing, China, 2021: A Real-World Study. Vaccines, 2022, 10, 571.	2.1	2
163	Strategies and safety considerations of booster vaccination in COVID-19. Bosnian Journal of Basic Medical Sciences, 2022, , .	0.6	5

#	Article	IF	Citations
164	Adverse Effects and Antibody Titers in Response to the BNT162b2 mRNA COVID-19 Vaccine in a Prospective Study of Healthcare Workers. Open Forum Infectious Diseases, 2022, 9, ofab575.	0.4	43
165	Assessment of Post-Vaccination Antibody Response Eight Months after the Administration of BNT1622b2 Vaccine to Healthcare Workers with Particular Emphasis on the Impact of Previous COVID-19 Infection. Vaccines, 2021, 9, 1508.	2.1	12
166	COVID-19 mRNA Based Vaccine Immune-Response Assessment in Nursing Home Residents for Public Health Decision. Vaccines, 2021, 9, 1429.	2.1	4
167	Durable humoral responses after the second antiâ€SARSâ€CoVâ€2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors. British Journal of Haematology, 2022, 197, .	1.2	13
169	Persistence of Robust Humoral Immune Response in Coronavirus Disease 2019 Convalescent Individuals Over 12 Months After Infection. Open Forum Infectious Diseases, 2022, 9, ofab626.	0.4	6
170	Anti-SARS-CoV-2 S-RBD IgG Antibody Responses after COVID-19 mRNA Vaccine in the Chronic Disorder of Consciousness: A Pilot Study. Journal of Clinical Medicine, 2021, 10, 5830.	1.0	1
171	Rapid decay of anti-SARS-CoV-2 antibodies in infection-naÃ¯ve healthcare workers four months after vaccination. Germs, 2021, 11, 625-629.	0.5	4
172	Why promoting a COVID-19 vaccine booster dose?. Anaesthesia, Critical Care & Pain Medicine, 2021, 40, 100967.	0.6	18
175	Immunogenicity and clinical features relating to BNT162b2 messenger RNA COVID-19 vaccine, Ad26.COV2.S and ChAdOx1 adenoviral vector COVID-19 vaccines: a systematic review of non-interventional studies. Future Journal of Pharmaceutical Sciences, 2022, 8, 20.	1.1	2
176	Differences in Humoral and Cellular Vaccine Responses to SARS-CoV-2 in Kidney and Liver Transplant Recipients. Frontiers in Immunology, 2022, 13, 853682.	2.2	13
177	Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study. Hepatology International, 2022, 16, 691-701.	1.9	23
178	Persistence of SARS-CoV-2 Antibodies in Vaccinated Health Care Workers Analyzed by Coronavirus Antigen Microarray. Frontiers in Immunology, 2022, 13, 817345.	2.2	5
179	BNT162b2, mRNA-1273, and Sputnik V Vaccines Induce Comparable Immune Responses on a Par With Severe Course of COVID-19. Frontiers in Immunology, 2022, 13, 797918.	2.2	1
180	Predictors of SARS-CoV-2 IgG Spike Antibody Responses on Admission and Clinical Outcomes of COVID-19 Disease in Fully Vaccinated Inpatients: The CoVax Study. Journal of Personalized Medicine, 2022, 12, 640.	1.1	3
181	Changing Patterns of SARS-CoV-2 Seroprevalence among Canadian Blood Donors during the Vaccine Era. Microbiology Spectrum, 2022, 10, e0033922.	1.2	9
182	Immunogenicity of an AAV-Based COVID-19 Vaccine in Murine Models of Obesity and Aging. Viruses, 2022, 14, 820.	1.5	1
183	Blood Antibody Titers and Adverse Reactions after BNT162b2 mRNA Vaccination. Vaccines, 2022, 10, 640.	2.1	0
184	Risk of strong antibody decline in dialysis and transplant patients after SARS-CoV-2mRNA vaccination: Six months data from the observational Dia-Vacc study. Lancet Regional Health - Europe, The, 2022, 17, 100371.	3.0	10

#	Article	IF	Citations
185	Immunogenicity against the BNT162b2 mRNA COVID-19 Vaccine in Rheumatic Disease Patients Receiving Immunosuppressive Therapy. Internal Medicine, 2022, 61, 1953-1958.	0.3	7
186	Anti-SARS-CoV-2 IgG antibodies induced by the BNT162b2 mRNA vaccine is age-dependent and influenced by a previous natural SARS-CoV-2 infection.. Acta Biomedica, 2022, 92, e2021464.	0.2	0
187	Ethical Issues involving the development of Covid-19 vaccines: Role of vaccine development, clinical trials and speed of peer review in dissuading public vaccine hesitancy. Ethics in Biology, Engineering & Medicine, 2022, , .	0.1	0
188	Complete (Humoral and Cellular) Response to Vaccination against COVID-19 in a Group of Healthcare Workers-Assessment of Factors Affecting Immunogenicity. Vaccines, 2022, 10, 710.	2.1	9
189	Serosurveillance among healthcare workers vaccinated with ChAdOx1 nCoV-19 Corona vaccine in a tertiary hospital of Kerala, India: prospective cohort studÑƒ. SeÄenovskij Vestnik, 2021, 13, 14-23.	0.3	0
190	Age and sex associations of SARS-CoV-2 antibody responses post BNT162b2 vaccination in healthcare workers: A mixed effects model across two vaccination periods. PLoS ONE, 2022, 17, e0266958.	1.1	25
191	SARS-CoV-2 Antibody and T Cell Response after a Third Vaccine Dose in Hemodialysis Patients Compared with Healthy Controls. Vaccines, 2022, 10, 694.	2.1	6
192	Early and Longitudinal Humoral Response to the SARS-CoV-2 mRNA BNT162b2 Vaccine in Healthcare Workers: Significance of BMI, Adipose Tissue and Muscle Mass on Long-Lasting Post-Vaccinal Immunity. Viruses, 2022, 14, 868.	1.5	6
193	The Epidemiological, Clinical Features and Outcomes of Imported Chinese COVID-19 Patients Following Inactivated Vaccines Injection. Infection and Drug Resistance, 2022, Volume 15, 2115-2125.	1.1	2
194	Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine. JAMA Network Open, 2022, 5, e2210780.	2.8	27
195	Humoral Response to BNT162b2 Vaccine Against SARS-CoV-2 Variants Decays After Six Months. Frontiers in Immunology, 2022, 13, 879036.	2.2	13
196	Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third Dose. Journal of Infectious Diseases, 2022, 226, 983-994.	1.9	26
197	COVID-19 vaccine development: milestones, lessons and prospects. Signal Transduction and Targeted Therapy, 2022, 7, 146.	7.1	153
198	Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine) Tj ETQq1 1 0.784314 rgBT /Overloc	0.8	3
199	Presence of SARS-CoV-2 antibodies following COVID-19 diagnosis: a longitudinal study of patients at a major urgent care provider in New York. Diagnostic Microbiology and Infectious Disease, 2022, 103, 115720.	0.8	2
201	Perspective: Role of Micronutrients and Omega-3 Long-Chain Polyunsaturated Fatty Acids for Immune Outcomes of Relevance to Infections in Older Adultsâ€"A Narrative Review and Call for Action. Advances in Nutrition, 2022, 13, 1415-1430.	2.9	9
202	Anti-SARS-CoV-2 antibodies among vaccinated healthcare workers: Repeated cross-sectional study. Journal of Family Medicine and Primary Care, 2022, 11, 1883.	0.3	4
203	Assessment of antibody titer and side effects after third doses of COVID-19 mRNA vaccination in healthy volunteers. Laboratoriums Medizin, 2022, 46, 171-177.	0.1	2

#	Article	IF	Citations
204	Effectiveness and Durability of mRNA Vaccine-Induced SARS-CoV-2-Specific Humoral and Cellular Immunity in Severe Asthma Patients on Biological Therapy. Frontiers in Immunology, 2022, 13, .	2.2	7
205	Post-Vaccination Seropositivity Against SARS-CoV-2 in Peruvian Health Workers Vaccinated with BBIBP-CorV (Sinopharm). SSRN Electronic Journal, 0, , .	0.4	0
206	Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in NaÃ¯ve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals. Frontiers in Immunology, 2022, 13, .	2.2	11
207	Assessing the Reliability of SARS-CoV-2 Neutralization Studies That Use Post-Vaccination Sera. Vaccines, 2022, 10, 850.	2.1	5
208	Heterogeneous SARS-CoV-2 humoral response after COVID-19 vaccination and/or infection in the general population. Scientific Reports, 2022, 12, .	1.6	8
209	Immunogenicity and Reactogenicity of mRNA BNT162b2 COVID-19 Vaccine among Thai Adolescents with Chronic Diseases. Vaccines, 2022, 10, 871.	2.1	13
210	The Effect of Age, Gender and Comorbidities Upon SARS-CoV-2 Spike Antibody Induction After Two Doses of Sinopharm Vaccine and the Effect of a Pfizer/BioNtech Booster Vaccine. Frontiers in Immunology, 2022, 13, .	2.2	10
211	Age-Related Dynamics of Serum Anti-Spike IgG Ab After the Third Dose of BNT162b2 Vaccine in a Naive Health Care Workers Population. Viral Immunology, 2022, 35, 386-389.	0.6	2
213	Hypertension is associated with antibody response and breakthrough infection in health care workers following vaccination with inactivated SARS-CoV-2. Vaccine, 2022, 40, 4046-4056.	1.7	24
215	Mouse models in COVID-19 research: analyzing the adaptive immune response. Medical Microbiology and Immunology, 2023, 212, 165-183.	2.6	6
216	Is the fourth COVID-19 vaccine dose urgently needed? Revelation from a prospective cohort study. Journal of Infection, 2022, 85, e66-e68.	1.7	5
217	The antiâ€“SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination. Science Translational Medicine, 2022, 14, .	5.8	19
218	Depending on Epitope Profile of COVID-19 mRNA Vaccine Recipients: Are They More Efficient Against the Arising Viral Variants? An Opinion Article. Frontiers in Medicine, 0, 9, .	1.2	0
219	Anticuerpos Anti SARS-CoV-2, Post-vacunaciÃ³n en Cochabamba, Bolivia. Gaceta Medica Boliviana, 2022, 45, 29-35.	0.0	0
220	Individuals With Weaker Antibody Responses After Booster Immunization Are Prone to Omicron Breakthrough Infections. Frontiers in Immunology, 0, 13, .	2.2	17
221	Comparison of commercial SARS-CoV-2 surrogate neutralization assays with a full virus endpoint dilution neutralization test in two different cohorts. Journal of Virological Methods, 2022, 307, 114569.	1.0	6
222	COVID-19 Vaccines: Update of the vaccines in use and under development. Vacunas, 2022, , .	1.1	6
223	A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222. Vaccines, 2022, 10, 914.	2.1	3

#	Article	IF	Citations
224	Safety and Immunogenicity of SII-NVX-CoV2373 (COVID-19 Vaccine) In Adults in a Phase 2/3, Observer-Blind, Randomised, Controlled Study. SSRN Electronic Journal, 0, , .	0.4	2
225	Establishment of an Easy and Convenient Anti-SARS-CoV-2 Neutralizing Antibodies Test Flow Starting from Community Pharmacies: Expansion of Pharmacy Functions Suitable During the Novel Coronavirus Era. BPB Reports, 2022, 5, 80-83.	0.1	0
226	Immune Responses Against SARS-CoV-2 WT and Delta Variant in Elderly BNT162b2 Vaccinees. Frontiers in Immunology, 0, 13, .	2.2	4
227	Differential Dynamics of Humoral and Cell-Mediated Immunity with Three Doses of BNT162b2 SARS-CoV-2 Vaccine in Healthcare Workers in Japan: A Prospective Cohort Study. Vaccines, 2022, 10, 1050.	2.1	3
228	Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial. Lancet Respiratory Medicine,the, 2022, 10, 840-850.	5.2	52
230	An Analysis of SARS-CoV-2 Vaccine Reactogenicity: Variation by Type, Dose, and History, Severity, and Recency of Prior SARS-CoV-2 Infection. Open Forum Infectious Diseases, 2022, 9, .	0.4	2
231	Effects of Obstructive Sleep Apnea on SARS-CoV-2 Antibody Response After Vaccination Against COVID-19 in Older Adults. Nature and Science of Sleep, 0, Volume 14, 1203-1211.	1.4	6
232	Paxlovid: Mechanism of Action, Synthesis, and In Silico Study. BioMed Research International, 2022, 2022, 1-16.	0.9	56
234	Association between IgG antibody levels and adverse events after first and second Bnt162b2 mRNA vaccine doses. Clinical Microbiology and Infection, 2022, 28, 1644-1648.	2.8	6
235	Immunity after COVID-19 Recovery and Vaccination: Similarities and Differences. Vaccines, 2022, 10, 1068.	2.1	9
236	Advances in COVID-19 Vaccines and New Coronavirus Variants. Frontiers in Medicine, 0, 9, .	1.2	4
237	Anti-SARS-CoV-2 Revaccination Success in Kidney Transplant Recipients With No Initial Humoral Response Is Linked to Primary Vaccine Type. Frontiers in Medicine, 0, 9, .	1.2	4
238	<scp>COVID</scp>â€19 and plasma cells: Is there longâ€lived protection?*. Immunological Reviews, 2022, 309, 40-63.	2.8	26
239	Depression, aging, and immunity: implications for COVID-19 vaccine immunogenicity. Immunity and Ageing, 2022, 19, .	1.8	6
240	Clinical characteristics and outcomes of critically ill patients with one, two and three doses of vaccination against COVIDâ€19 in Australia. Internal Medicine Journal, 2023, 53, 330-338.	0.5	8
241	MMF/MPA Is the Main Mediator of a Delayed Humoral Response With Reduced Antibody Decline in Kidney Transplant Recipients After SARS-CoV-2 mRNA Vaccination. Frontiers in Medicine, 0, 9, .	1.2	5
242	Understanding Immune Responses to Virusesâ€"Do Underlying Th1/Th2 Cell Biases Predict Outcome?. Viruses, 2022, 14, 1493.	1.5	20
243	The publicâ€™s attitude to and acceptance of periodic doses of the COVID-19 vaccine: A survey from Jordan. PLoS ONE, 2022, 17, e0271625.	1.1	8

#	Article	IF	Citations
244	Effectiveness of ComirnatyÂ® Vaccine and Correlates of Immunogenicity and Adverse Reactions: A Single-Center Prospective Case Series Study. Vaccines, 2022, 10, 1170.	2.1	2
245	Relationship between Side Effects of BNT162b2 Inoculation and IgG Antibody Titers. Journal of the Japanese Association for Infectious Diseases, 2022, 96, 125-131.	0.0	0
246	Decreased Levels of SARS-CoV-2 Fusion-Inhibitory Antibodies in the Serum of Aged COVID-19 Patients. Diagnostics, 2022, 12, 1813.	1.3	0
248	Effectiveness of SARS-CoV-2 Vaccines for Short- and Long-Term Immunity: A General Overview for the Pandemic Contrast. International Journal of Molecular Sciences, 2022, 23, 8485.	1.8	6
249	Outcome after single dose of ChAdOx1 vaccine against SARS-CoV-2 infection at 16 weeks post-vaccination among healthy adults in Saudi Arabia. Annals of Saudi Medicine, 2022, 42, 223-228.	0.5	0
250	BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults. Frontiers in Immunology, 0, 13, .	2.2	16
251	Inhaled corticosteroids do not affect the antibody titer against the SARS-CoV-2 spike protein in BNT162b2 mRNA vaccinated patients. Allergy, Asthma and Clinical Immunology, 2022, 18, .	0.9	2
252	Convalescent Plasma for COVID-19: A Single Center Prospective Experience with Serial Antibody Measurements and Review of the Literature. Pathogens, 2022, 11, 958.	1.2	0
253	Clinical Impact of Monoclonal Antibodies in the Treatment of High-Risk Patients with SARS-CoV-2 Breakthrough Infections: The ORCHESTRA Prospective Cohort Study. Biomedicines, 2022, 10, 2063.	1.4	2
254	Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses. Microbiology Spectrum, 2022, 10, .	1.2	7
255	COVID-19 vaccination, implications for PET/CT image interpretation and future perspectives. Clinical and Translational Imaging, 0, , .	1.1	0
257	Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. Nature Communications, 2022, 13, .	5.8	27
258	Immune defects associated with lower SARS-CoV-2 BNT162b2 mRNA vaccine response in aged people. JCI Insight, 2022, 7, .	2.3	10
259	Factors influencing neutralizing antibody titers elicited by coronavirus disease 2019 vaccines. Microbes and Infection, 2023, 25, 105044.	1.0	7
260	Efficacy, immunogenicity and safety of COVID-19 vaccines in older adults: a systematic review and meta-analysis. Frontiers in Immunology, 0, 13, .	2.2	15
261	Ipsilateral Radial Neuropathy after COVID-19 mRNA Vaccination in an Immunocompetent Young Man. Yonsei Medical Journal, 2022, 63, 966.	0.9	5
262	Seroepidemiological study of factors affecting anti-spike IgG antibody titers after a two-dose mRNA COVID-19 vaccination in 3744 healthy Japanese volunteers. Scientific Reports, 2022, 12, .	1.6	5
263	Immunogenicity profiling and distinct immune response in liver transplant recipients vaccinated with SARS-CoV-2 inactivated vaccines. Frontiers in Immunology, 0, 13, .	2.2	2

#	Article	IF	Citations
264	Associations of Immunogenicity and Reactogenicity After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine in the COVE and TeenCOVE Trials. Clinical Infectious Diseases, 2023, 76, 271-280.	2.9	3
265	Sinopharmâ€™s BBIBP-CorV Vaccine and ChAdOx1 nCoV-19 Vaccine Are Associated with a Comparable Immune Response against SARS-CoV-2. Vaccines, 2022, 10, 1462.	2.1	5
266	Reduced Antibody Acquisition with Increasing Age following Vaccination with BNT162b2: Results from Two Longitudinal Cohort Studies in The Netherlands. Vaccines, 2022, 10, 1480.	2.1	8
267	SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2: a 9Âmonths longitudinal study. Scientific Reports, 2022, 12, .	1.6	17
268	SARS-CoV-2 Spike and Nucleocapsid Antibody Response in Vaccinated Croatian Healthcare Workers and Infected Hospitalized Patients: A Single Center Cohort Study. Viruses, 2022, 14, 1966.	1.5	6
269	Correlation of Postvaccination Fever With Specific Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 BNT162b2 Booster and No Significant Influence of Antipyretic Medication. Open Forum Infectious Diseases, 2022, 9, .	0.4	5
270	Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection. Med, 2022, 3, 838-847.e3.	2.2	26
271	Hospital trajectories and early predictors of clinical outcomes differ between SARS-CoV-2 and influenza pneumonia. EBioMedicine, 2022, 85, 104295.	2.7	5
272	Declining Prevalence of SARS-CoV-2 Antibodies among Vaccinated Nursing Home Residents and Staff Six Months after the Primary BNT162b2 Vaccination Campaign in Belgium: A Prospective Cohort Study. Viruses, 2022, 14, 2361.	1.5	3
273	Antibody and T-Cell Subsets Analysis Unveils an Immune Profile Heterogeneity Mediating Long-term Responses in Individuals Vaccinated Against SARS-CoV-2. Journal of Infectious Diseases, 2023, 227, 353-363.	1.9	2
274	Third BNT162b2 Vaccine Booster Dose against SARS-CoV-2-Induced Antibody Response among Healthcare Workers. Vaccines, 2022, 10, 1741.	2.1	6
275	Effectiveness of BNT162b2 and CoronaVac vaccinations against SARS-CoV-2 omicron infection in people aged 60Âyears or above: a caseâ€“control study. Journal of Travel Medicine, 2022, 29, .	1.4	4
276	Anti SARS-CoV 2 IgG antibody response in fully vaccinated Covishield (AZD1222) and Covaxin (BBV-152) recipients: a study done in southern part of West Bengal, India. Iranian Journal of Microbiology, 0, , .	0.8	1
277	Impact of SARS-CoV-2 pandemic on rehabilitation of patients after high-dose chemotherapy with allogeneic hematopoietic stem cell transplantation: results of a monocentric, retrospective analysis. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	0
279	COVID-19 Vaccination Trends and Side Effects among Egyptian Hemodialysis Patients: A Multicenter Survey Study. Vaccines, 2022, 10, 1771.	2.1	0
280	Systemic and Mucosal Humoral Immune Response Induced by Three Doses of the BNT162b2 SARS-CoV-2 mRNA Vaccines. Vaccines, 2022, 10, 1649.	2.1	3
281	Fully understanding the efficacy profile of the COVID-19 vaccination and its associated factors in multiple real-world settings. Frontiers in Immunology, 0, 13, .	2.2	5
282	The Risk Factors of SARS-CoV-2 Antibody Level Differences in Healthcare Workers Post Vaccination in Siloam Hospitals: A Nationwide Multicenter Study.. , 2022, , .		0

#	Article	IF	Citations
283	Adjusted COVID-19 booster schedules balance age-dependent differences in antibody titers benefitting risk populations. Frontiers in Aging, 0, 3, .	1.2	1
284	Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020â€“March 2022. Emerging Infectious Diseases, 2022, 28, 2198-2205.	2.0	4
285	MULTI-PARAMETRIC PREDICTION MODELS FOR COVID-19 VACCINE SELECTION: RESULTS OF A COMPARATIVE POPULATION-BASED COHORT STUDY. Clinical Infectious Diseases, 0, , .	2.9	0
286	Induction of cross-reactive, mucosal anti-SARS-CoV-2 antibody responses in rheumatoid arthritis patients after 3rd dose of COVID-19 vaccination. Journal of Autoimmunity, 2022, 133, 102918.	3.0	1
287	Quantifying the Vaccine-Induced Humoral Immune Response to Spike-Receptor Binding Domain as a Surrogate for Neutralization Testing Following mRNA-1273 (Spikevax) Vaccination Against COVID-19. Infectious Diseases and Therapy, 2023, 12, 177-191.	1.8	2
288	Immunogenicity of an mRNA-Based COVID-19 Vaccine among Adolescents with Obesity or Liver Transplants. Vaccines, 2022, 10, 1867.	2.1	6
289	Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey. Scientific Reports, 2022, 12, .	1.6	4
290	Vaccines for the Prevention of Coronavirus Disease 2019 in Older Adults. Infectious Disease Clinics of North America, 2023, 37, 27-45.	1.9	6
291	Changes in spike protein antibody titer over 90 days after the second dose of SARS-CoV-2 vaccine in Japanese dialysis patients. BMC Infectious Diseases, 2022, 22, .	1.3	0
292	Aging, inflammaging and immunosenescence as risk factors of severe COVID-19. Immunity and Ageing, 2022, 19, .	1.8	28
293	Do we need to vaccinate every child against COVID-19: What evidence suggestsâ€”A systematic review of opinions. Frontiers in Public Health, 0, 10, .	1.3	9
294	Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities. Npj Vaccines, 2022, 7, .	2.9	10
295	Post-vaccination seropositivity against SARS-CoV-2 in peruvian health workers vaccinated with BBIBP-CorV (Sinopharm). Travel Medicine and Infectious Disease, 2023, 52, 102514.	1.5	3
296	COVID-19 vaccines: Update of the vaccines in use and under development. Vacunas (English Edition), 2022, 23, S88-S102.	0.3	0
297	SARS-CoV-2 Specific Humoral Immune Responses after BNT162b2 Vaccination in Hospital Healthcare Workers. Vaccines, 2022, 10, 2038.	2.1	2
298	Using nanomaterials to address SARS-CoV-2 variants through development of vaccines and therapeutics. Frontiers in Materials, 0, 9, .	1.2	0
299	Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study. PLoS Medicine, 2022, 19, e1004037.	3.9	28
300	Effect of the third dose of BNT162b2 COVID-19 mRNA vaccine on anti-SARS-CoV-2 antibody levels in healthcare workers. Vaccine, 2023, 41, 365-371.	1.7	3

#	Article	IF	Citations
301	Prevalence of SARS-CoV-2 antibodies among Belgian nursing home residents and staff during the primary COVID-19 vaccination campaign. European Journal of General Practice, 2023, 29, .	0.9	2
302	Comparative analysis of the effectiveness of vaccines against SARS-CoV-2 3 months after revaccination. NacionalÊ¹noe Zdravoohranenie, 2022, 3, 32-35.	0.3	0
303	Determinants of the Level of Anti-SARS-CoV-2 IgG ANTibodiEs after Vaccination (DANTE-SIRIO 7) Study in a Large Cohort of Healthcare Workers. Vaccines, 2022, 10, 2125.	2.1	0
304	Serological Responses up to 9 Months following COVID-19 mRNA Vaccination in Residents and Health-Care Workers of Long-Term Care Facilities: A Multicenter Prospective Cohort Study in Northern Italy. Vaccines, 2022, 10, 2183.	2.1	2
306	Clinical characteristics and severity of beta and delta variants of SARS-CoV-2 and the effect of vaccine on delta variants. Heliyon, 2022, 8, e12594.	1.4	1
307	Serology results after COVID vaccine in multiple sclerosis patients treated with fingolimod. Revue Neurologique, 2022, , .	0.6	0
308	Risk of waning humoral responses after inactivated or subunit recombinant SARSâ€CoVâ€2 vaccination in patients with chronic diseases: Findings from a prospective observational study in China. Journal of Medical Virology, 2023, 95, .	2.5	5
309	Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic disease. RMD Open, 2022, 8, e002650.	1.8	10
310	Durability of humoral and cellâ€mediated immune response after SARSâ€CoVâ€2 mRNA vaccine administration. Journal of Medical Virology, 2023, 95, .	2.5	5
311	Evaluation of SARS-CoV-2 Antibody Levels in Pharmacists and Pharmacy Staff Following CoronaVac Vaccination. Turkish Journal of Pharmaceutical Sciences, 2024, 20, 347-351.	0.6	0
312	Correlates of SARSâ€CoVâ€2 antiâ€RBD IgG antibody titers among persons experiencing homelessness in Los Angeles. Public Health Nursing, 2023, 40, 417-427.	0.7	0
313	An extended SARS-CoV-2 mRNA vaccine prime-boost interval enhances B cell immunity with limited impact on T cells. IScience, 2023, 26, 105904.	1.9	9
314	No difference in anti-spike antibody and surrogate viral neutralization following SARS-CoV-2 booster vaccination in persons with HIV compared to controls (CO-HIV Study). Frontiers in Immunology, 0, 13, .	2.2	5
315	Predictive Value of Reactogenicity for Anti-SARS-CoV-2 Antibody Response in mRNA-1273 Recipients: A Multicenter Prospective Cohort Study. Vaccines, 2023, 11, 120.	2.1	4
316	COVID-19 Vaccinesâ€"All You Want to Know. Seminars in Respiratory and Critical Care Medicine, 2023, 44, 143-172.	0.8	4
317	Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study. , 2023, 10, 100139.		7
318	Kinetics of Anti-SARS-CoV-2 Antibody Response Following Two Doses of the BNT162b2 mRNA Vaccine: A Japanese Single-Center Primary Care Clinic Report Involving Volunteers and Patients with Autoimmune Disease. Infectious Disease Reports, 2023, 15, 24-33.	1.5	0
319	Antibody response to third and fourth BNT162b2 mRNA booster vaccinations in healthcare workers in Tokyo, Japan. Journal of Infection and Chemotherapy, 2023, 29, 339-346.	0.8	1

#	Article	IF	Citations
320	Seroprevalence of anti-SARS-CoV-2 specific antibodies in vaccinated and vaccine naÃ¯ve adult Nigerians. PLoS ONE, 2023, 18, e0280276.	1.1	2
321	The Influence of Booster Shot and SARS-CoV-2 Infection on the Anti-Spike Antibody Concentration One Year after the First COVID-19 Vaccine Dose Administration. Vaccines, 2023, 11, 278.	2.1	0
322	Immunogenicity, effectiveness and safety of COVID-19 vaccine in older adults living in nursing homes: A real-life study. Revista Espanola De Geriatria Y Gerontologia, 2023, 58, 125-133.	0.2	4
323	Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort. Vaccine, 2023, 41, 2234-2242.	1.7	7
324	Antibody response dynamics to CoronaVac vaccine and booster immunization in adults and the elderly: a long-term, longitudinal prospective study. IJID Regions, 2023, , .	0.5	0
325	Impaired Humoral Immunity Identified in Inactivated SARS-CoV-2 Vaccine Recipients without Anti-Spike RBD Antibodies. Microbiology Spectrum, 2023, 11, .	1.2	0
326	Immunogenicity of a Third Dose of BNT162b2 Vaccine among Lung Transplant Recipientsâ€"A Prospective Cohort Study. Vaccines, 2023, 11, 799.	2.1	0
327	Cirrhosis is associated with lower serological responses to COVID-19 vaccines in patients with chronic liver disease. JHEP Reports, 2023, 5, 100697.	2.6	7
328	Antibody acquisition after second and third SARS-CoV-2 vaccinations in Japanese kidney transplant patients: a prospective study. Clinical and Experimental Nephrology, 0, , .	0.7	0
329	Modelling the impact of the Omicron BA.5 subvariant in New Zealand. Journal of the Royal Society Interface, 2023, 20, .	1.5	9
330	Frailty Reduces Vaccine Effectiveness Against SARS-CoV-2 Infection: A Test-Negative Case Control Study Using National VA Data. Journal of Nutrition, Health and Aging, 2023, 27, 81-88.	1.5	4
331	Safety and immunogenicity of inactivated COVID-19 vaccine CoronaVac and the RBD-dimerâ€"based COVID-19 vaccine ZF2001 in chronic hepatitis B patients. Frontiers in Medicine, 0, 10, .	1.2	0
333	Predictors for reactogenicity and humoral immunity to SARS-CoV-2 following infection and mRNA vaccination: A regularized, mixed-effects modelling approach. Frontiers in Immunology, 0, 14, .	2.2	1
334	Antibody responses to BNT162b2 SARSâ€CoVâ€2 mRNA vaccine among healthcare workers and residents of longâ€term care facilities: A cohort study in Northern Italy. Health Science Reports, 2023, 6, .	0.6	0
335	Age and Cytokine Gene Variants Modulate the Immunogenicity and Protective Effect of SARS-CoV-2 mRNA-Based Vaccination. Vaccines, 2023, 11, 413.	2.1	1
336	Human brain organoids to explore SARSâ€CoVâ€2â€induced effects on the central nervous system. Reviews in Medical Virology, 2023, 33, .	3.9	7
337	HLA-I and HLA-II Peptidomes of SARS-CoV-2: A Review. Vaccines, 2023, 11, 548.	2.1	1
338	Comparison of Immunogenicity and Reactogenicity of Five Primary Series of COVID-19 Vaccine Regimens against Circulating SARS-CoV-2 Variants of Concern among Healthy Thai Populations. Vaccines, 2023, 11, 564.	2.1	1

#	Article	IF	Citations
339	Antibody Responses to the SARS-CoV-2 Ancestral Strain and Omicron Variants in Moderna mRNA-1273 Vaccinated Active-Duty US Navy Sailors and Marines. Journal of Infectious Diseases, 2023, 228, 149-159.	1.9	3
340	Higher plasma levels of thymosin-Î±1 are associated with a lower waning of humoral response after COVID-19 vaccination: an eight months follow-up study in a nursing home. Immunity and Ageing, 2023, 20, .	1.8	1
342	SARS-CoV-2 antibody responses associate with sex, age and disease severity in previously uninfected people admitted to hospital with COVID-19: An ISARIC4C prospective study. Frontiers in Immunology, 0, 14, .	2.2	4
343	Efficient virus detection utilizing chitin-immobilized nanobodies synthesized in Ustilago maydis. Journal of Biotechnology, 2023, 366, 72-84.	1.9	1
344	Response and duration of serum antiâ€SARSâ€CoVâ€2 antibodies induced by the third dose of an inactivated vaccine: A prospective longitudinal cohort study at 21 serial time points over 641 days. Journal of Medical Virology, 2023, 95, .	2.5	0
345	COVID-19 vaccine antibody responses in community-dwelling adults to 48Âweeks post primary vaccine series. IScience, 2023, 26, 106506.	1.9	4
346	COVID-19 vaccination and case fatality rates: a case report in a Brazilian municipality. Cadernos De Saude Publica, 2023, 39, .	0.4	0
348	Immune correlates of protection for SARS-CoV-2, Ebola and Nipah virus infection. Frontiers in Immunology, 0, 14, .	2.2	7
349	Longitudinal Changes in IgG-Type SARS-CoV-2 Antibody Titers after COVID-19 Vaccination and a Prominent Increase in Antibody Titers When Infected after Vaccination. Vaccines, 2023, 11, 860.	2.1	2
350	Trends in Antibody Titers after SARS-CoV-2 Vaccinationâ€"Insights from Self-Paid Tests at a General Internal Medicine Clinic. Medicines (Basel, Switzerland), 2023, 10, 27.	0.7	3
351	Dietary intervention with functional foods modulating gut microbiota for improving the efficacy of COVID-19 vaccines. Heliyon, 2023, 9, e15668.	1.4	5